Saga Natura
Focusing on consumer health products from microalgae.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $2.4m | Seed | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 400 % | 300 % | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1000 %) | (140 %) | (50 %) | 5 % | 10 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 100 % | 40 % | 50 % | 50 % | 100 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Based in Hafnarfjordur, Iceland, Saga Natura is a biotechnology company focused on producing consumer health products and food supplements from natural Icelandic ingredients. Established in 2000 by a group of food and pharmaceutical professionals, the company was originally known as SagaMedica. Over its more than two-decade history, Saga Natura has leveraged scientific research and new technologies to create unique product blends from natural raw materials. The firm has secured approximately $6.98 million in funding from various sources, including venture capital and grants from entities like the European Union's Horizon 2020 program, Eyrir Venture Management, and the Icelandic Technology Development Fund.
The company's business model is vertically integrated, controlling the process from raw material to finished product. Saga Natura operates in the nutraceutical and e-commerce sectors, generating revenue through the direct sale of its consumer products and by supplying active compounds, such as extracts and oils, to other businesses in the supplement and nutraceutical fields. In a strategic move to expand its international market presence, Saga Natura merged with Icelandic herbal medicine company Florealis in September 2023, with Saga Natura's shareholders acquiring a 64.5% stake in Florealis.
Saga Natura's product portfolio is centered around two key ingredients: Archangelica angelica and Astaxanthin. The company has studied the bioactive compounds in the wild-growing Archangelica angelica for nearly three decades, developing products like SAGAPRO®, a supplement for urinary health. Their Icelandic Astaxanthin, branded as AstaKey™, is a powerful antioxidant harvested from freshwater microalgae using a sustainable, closed-tank system powered by renewable energy. This technology ensures a pure, natural, and vegan-friendly product, which is featured in supplements for skin health, like AstaSkin, and eye health. The company offers a range of other supplements, including collagen, omega-3, and various vitamins.
Keywords: nutraceuticals, biotechnology, Icelandic supplements, Astaxanthin, Archangelica Angelica, consumer health products, food supplements, natural ingredients, sustainable harvesting, dietary supplements, herbal medicine, urinary health, skin health, antioxidant, e-commerce, B2C, B2B, plant-based health, microalgae, European Union Horizon 2020, Florealis merger, AstaKey, SAGAPRO